ASCO: Intismeran Plus Pembrolizumab Ups RFS, DMFS in High-Risk Melanoma

MONDAY, June 1, 2026 -- For patients with resected high-risk melanoma, intismeran plus pembrolizumab offers clinically meaningful improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) compared with pembrolizumab...